Search
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Fortune 500
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Roivant Sciences
Roivant Sciences
Health
How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs
By
Sy Mukherjee
September 21, 2017
Health
Why SoftBank Made a Record-Breaking $1.1 Billion Bet on This Biotech Firm
By
Sy Mukherjee
August 9, 2017
Health
This 31-Year-Old CEO Is Snapping Up Drug Industry Veterans Left and Right
By
Sy Mukherjee
July 10, 2017
Health
This 31-Year-Old Just Launched His 5th Biotech Company With a Boost From Merck
By
Sy Mukherjee
June 6, 2017
Most Popular
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By
Nino Paoli
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in...
By
Nino Paoli
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House...
By
Jason Ma
